Changes in SARS-CoV-2 antibody titers 6 months after the booster dose of BNT162b2 COVID-19 vaccine among health care workers.
COVID-19 vaccine booster
Health care workers
Japan
SARS-CoV-2 antibody titer
Journal
Clinical and experimental vaccine research
ISSN: 2287-3651
Titre abrégé: Clin Exp Vaccine Res
Pays: Korea (South)
ID NLM: 101592344
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
24
09
2022
revised:
09
01
2023
accepted:
31
03
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
In Japan, the data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers after the booster dose of the coronavirus disease 2019 (COVID-19) vaccine are insufficient. The aim of this study is to evaluate changes in SARS-CoV-2 antibody titers before, 1, 3, and 6 months after the booster dose of the BNT162b2 COVID-19 vaccine among health care workers. A total of 268 participants who received the booster dose of the BNT162b2 vaccine were analyzed. SARS-CoV-2 antibody titers were measured before (baseline) and at 1, 3, and 6 months after the booster dose. Factors associated with changes in SARS-CoV-2 antibody titers at 1, 3, and 6 months were analyzed. Cutoff values at baseline were calculated to prevent infection of the omicron variant of COVID-19. The SARS-CoV-2 antibody titers at baseline, and 1, 3, and 6 months were 1,018.3 AU/mL, 21,396.5 AU/mL, 13,704.6 AU/mL, and 8,155.6 AU/mL, respectively. Factors associated with changes in SARS-CoV-2 antibody titers at 1 month were age and SARS-CoV-2 antibody titers at baseline, whereas changes in SARS-CoV-2 antibody titers at 3 and 6 months were associated with the SARS-CoV-2 antibody titers at 1 month. The cutoff values of the SARS-CoV-2 antibody titers at baseline were 515.4 AU/mL and 13,602.7 AU/mL at baseline and 1 month after the booster dose, respectively. This study showed that SARS-CoV-2 antibody titers increase rapidly at 1 month after the booster dose of the BNT162b2 vaccine and begin to decrease from 1 to 6 months. Hence, another booster may be needed as soon as possible to prevent infection.
Identifiants
pubmed: 37214144
doi: 10.7774/cevr.2023.12.2.116
pmc: PMC10193111
doi:
Types de publication
Journal Article
Langues
eng
Pagination
116-120Informations de copyright
© Korean Vaccine Society.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Lancet Reg Health Am. 2022 Apr;8:100227
pubmed: 35313615
Anaesth Crit Care Pain Med. 2021 Dec;40(6):100967
pubmed: 34924154
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
J Korean Med Sci. 2022 Mar 07;37(9):e70
pubmed: 35257525
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
N Engl J Med. 2022 Apr 21;386(16):1579-1580
pubmed: 35294809
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Lancet Reg Health Am. 2022 May;9:100198
pubmed: 35187521
Clin Chem Lab Med. 2021 Dec 16;60(3):456-463
pubmed: 34911170
N Engl J Med. 2022 May 19;386(20):1910-1921
pubmed: 35320659
Intern Med. 2022 Apr 15;61(8):1139-1143
pubmed: 35185050
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Eur Geriatr Med. 2022 Feb;13(1):275-278
pubmed: 35067909